2022 12 19 predictions-for-2023 
HIT Consultant
JANUARY 15, 2024
What You Should Know: – The US healthcare industry, after weathering a storm of inflation, labor shortages, and lingering COVID-19 impacts in 2023, is now showing signs of a promising rebound, according to a new repor t by McKinsey & Company. This shift fuels a 5% CAGR for payer profit pools, reaching $78 billion by 2027.
NASHP
NOVEMBER 2, 2022
Apply Today to NASHP’s 2023 Emerging Leaders of Color Fellowship November 7, 2022. Previous Next Alyzah Virani, 2022 ELC fellow “Being selected for NASHP’s Emerging Leader of Color Fellowship was not something I had predicted, and my experience became one of the most formative ones of my professional career.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
HIT Consultant
JULY 17, 2023
So, with the end of the public health emergency (PHE) on May 11, 2023, and the cessation of PHE-related exceptions that increased access to mental health resources, there is reason for concern. And an analysis from the Kaiser Family Foundation found Medicaid/CHIP enrollment increased 29% from February 2020 to November 2022.
HIT Consultant
NOVEMBER 4, 2022
– Market research leader Forrester’s latest report explores 5 key predictors for healthcare in 2023. COVID-19 changed how consumers and brands do business, and healthcare organizations are no exception; the pandemic accelerated transformation by a decade. Healthcare in the Era Post-Covid.
NASHP
MAY 8, 2023
Cox’s One Utah Roadmap and the urgent need for data-informed COVID-19 response, the Utah Department of Health and Human Services (DHHS) Office of Health Equity (OHE) prioritized a suite of data collection, analysis, and reporting initiatives. National efforts to standardize are useful to inform state approaches.
Home Health Care
JANUARY 17, 2022
Read on to learn more about: — The major policy and regulatory issues impacting home health and home care in 2022. — Dombi’s predictions on what “the next evolution” of home health care will look like. Bill, I think we’re going to be focusing most of this conversation on 2022. starting with Choose Home.
Health Advances
FEBRUARY 22, 2023
The most key patents of the product expired in January 2023. There are currently 10 manufacturers poised to launch biosimilars this year, including Amgen’s much-anticipated Amjevita which launched on January 31, 2023. It is projected that biosimilars have the potential to reduce spending on biologics by $38.4B
Expert insights. Personalized for you.
104 
Let's personalize your content